Tunlametinib+PD-1 mAb

DRUG2 trials

Sponsors

Fudan University, Sun Yat-sen University

Conditions

Advanced PDTC or ATC With NRAS MutationGastric AdenocarcinomaRadioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation

Phase 2

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

RecruitingNCT06970353

Fudan UniversityAdvanced PDTC or ATC With NRAS Mutation, Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation

Start: 2025-05-27End: 2031-12-30Target: 40Updated: 2025-08-07

A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer

Not yet recruitingNCT07507526

Sun Yat-sen UniversityGastric Adenocarcinoma

Start: 2026-04-01End: 2028-04-30Target: 76Updated: 2026-04-02